Showing results (41-50 of 163) with videos related to

Sort By:
Pageof 17
Cardiovascular and Interventional Radiology|August 16, 2017
CT-Guided Percutaneous Trans-scapular Lung Biopsy in the Diagnosis of Peripheral Pulmonary Lesion Nodules of the Superior Lobes Using Large NeedlesAlberto Rebonato, Daniele Maiettini, Marco Andolfi, et al.
Frontiers in Oncology|July 1, 2022
Beyond Crizotinib: A Systematic Review and Meta-Analysis of the Next-Generation ALK Inhibitors as First-Line Treatment for ALK-Translocated Lung CancerEmilio Francesco Giunta, Alessio Signori, Howard Jack West, et al.
Critical Reviews in Oncology/Hematology|December 22, 2023
Clinical evidence and adverse event management update of patients with RET- rearranged advanced non-small-cell lung cancer (NSCLC) treated with pralsetinibGiuseppe Lo Russo, Paolo Bironzo, Chiara Bennati, et al.
Critical Reviews in Oncology/Hematology|March 15, 2006
Clinical experience with gefitinib: an updateFederico Cappuzzo, Giovanna Finocchiaro, Giulio Metro, et al.
Mayo Clinic Proceedings|August 6, 2017
Large Cell Neuroendocrine Carcinoma Transformation and EGFR-T790M Mutation as Coexisting Mechanisms of Acquired Resistance to EGFR-TKIs in Lung CancerSara Baglivo, Vienna Ludovini, Angelo Sidoni, et al.
Tumori|May 13, 2017
Pathogenesis, clinical manifestations and management of immune checkpoint inhibitors toxicityAlessandro Inno, Giulio Metro, Paolo Bironzo, et al.
Expert Opinion on Emerging Drugs|April 4, 2024
Non-small cell lung cancer: an update on emerging EGFR-targeted therapiesValentina Favorito, Ilaria Ricciotti, Andrea De Giglio, et al.
Translational Lung Cancer Research|September 12, 2022
Efficacy and safety of anlotinib combined with carboplatin and pemetrexed as first-line induction therapy followed by anlotinib plus pemetrexed as maintenance therapy in <i>EGFR/ALK</i> wild-type advanced non-squamous non-small cell lung cancer in China: a multicenter, single-arm trialZhen He, Xiuli Yang, Tianjiang Ma, et al.
Reviews on Recent Clinical Trials|April 9, 2008
Epidermal growth factor receptor (EGFR) targeted therapies in non-small cell lung cancer (NSCLC)Giulio Metro, Giovanna Finocchiaro, Luca Toschi, et al.
Lung Cancer (Amsterdam, Netherlands)|January 21, 2015
Future options for ALK-positive non-small cell lung cancerDaniela Iacono, Rita Chiari, Giulio Metro, et al.
Pageof 17